Evidence mapPaperPMID 42589412Full record

ReviewInternational journal of molecular sciences2026

Artificial Intelligence and Genomic Data Analysis: New Frontiers in Precision Medicine.

Alexandra-Maria Blaga, Răzvan-Octavian Mihuț, Andreea-Ramona Treteanu, Octavian Andronic, Ștefan Sebastian Busnatu, Simona Dima, Viorica-Elena Rădoi

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexandra-Maria BlagaFaculty of Informatics and Sciences, University of Oradea, 410087 Oradea, Romania.ORCID 0009-0004-0990-5022
Răzvan-Octavian MihuțFaculty of Informatics and Sciences, University of Oradea, 410087 Oradea, Romania.ORCID 0009-0003-3843-7793
Andreea-Ramona TreteanuFaculty of General Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.ORCID 0009-0006-9232-8063
Octavian AndronicFaculty of General Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.ORCID 0000-0002-9053-0018
Ștefan Sebastian BusnatuFaculty of General Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.ORCID 0000-0002-4678-9655
Simona DimaFaculty of General Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Viorica-Elena RădoiFaculty of General Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid expansion of next-generation sequencing technologies has generated unprecedented volumes of genomic data; however, translating these data into reliable and clinically actionable insights remains a major challenge in precision medicine. Artificial intelligence (AI) has emerged as a key enabling technology across the genomic medicine pipeline, supporting variant detection, variant interpretation, polygenic risk prediction, disease subtyping, biomarker discovery and treatment-response modelling. This review provides a clinically oriented, pipeline-based synthesis of contemporary AI applications in genomic medicine. Major computational paradigms, including machine learning, deep learning, ensemble methods, multimodal AI, explainable AI frameworks and emerging foundation models, are discussed in the context of their contribution to genomic analysis and clinical decision support. Particular emphasis is placed on the factors that determine model robustness and clinical utility, including dataset composition, class imbalance, label noise, calibration, ancestry representation, distributional shift and external validation. Evidence from rare genetic disorders, cardiovascular genetics and precision oncology is examined to illustrate both successful translational applications and persistent barriers to implementation. The review further analyses common sources of failure in real-world genomic AI systems, including overfitting, limited transportability across populations and sequencing environments, inadequate interpretability, and insufficient prospective validation. Ethical and regulatory challenges are discussed in relation to clinical accountability, genomic privacy, algorithmic bias and equitable implementation. Ultimately, the successful clinical translation of genomic AI will depend not only on methodological innovation, but also on rigorous validation, transparent reporting, continuous calibration, robust governance and sustained expert oversight.

Indexed as

Artificial IntelligenceGenomic MedicineGenomicsPrecision MedicineData AnalysisHigh-Throughput Nucleotide SequencingHumansMachine LearningAIartificial intelligencecancergenetic variantsgenomic biomarkersprecision medicinevariant interpretation

Identifiers

PMID42589412
PMCPMC13466677

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.